Nuvectis Pharma Q3 2026 net loss widens to USD 30.07 million
Bitget2026/11/04 12:13- Nuvectis Pharma’s third-quarter 2026 net loss widened to $30.07 million.
- Research and development expenses rose to $27.37 million, primarily driven by a $20 million upfront payment for NXP100 and NXP200 licensing.
- Cash and cash equivalents reached $140.71 million at September 30, with funding expected to support operations into the second half of 2029.
- An FDA update on ciprocopan’s U.S. PNH pathway and U.S. IND submissions for NXP100 and NXP200 are expected by year-end.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Quantumrail Cancels 10 Billion Won Convertible Bond Offering
Crypto prices
More
